A carregar...
Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious
BACKGROUND: A median progression free survival (PFS) of 18–20 months and median overall survival (OS) of 51–57 months can be achieved with the use of imatinib, in metastatic or advanced gastrointestinal stromal tumor (GIST). Sunitinib and regorafenib are approved options for patients progressing on...
Na minha lista:
| Publicado no: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4963378/ https://ncbi.nlm.nih.gov/pubmed/27563456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.06 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|